Abstract:

Emerging management and its impact on radioiodine refractory differentiated thyroid cancer        LIU Yan-qing, LIN Yan-song. Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences，Beijing 100730， China
Corresponding author: LIN Yan-song，E-mail：linys@pumch.cn
Abstract    Differentiated thyroid cancer （DTC） generally carries good prognosis through standard treatment. While，it could dedifferentiate into radioiodine refractory differentiated thyroid cancer （RAIR-DTC），which progresses rapidly with high mortality and limited treatment methods. Recently，along with the increasing of studies on genetic features，signal transduction pathways and immune microenvironment of RAIR-DTC，as well as the development of new radionuclide tracers，more theoretical bases have been provided for the targeted therapy of RAIR-DTC.

Key words: radioiodine refractory differentiated thyroid cancer, targeted therapy, immunotherapy, peptide receptor radionuclide therapy

摘要：

分化型甲状腺癌经规范治疗总体预后良好，然而当其失分化为碘难治性甲状腺癌（RAIR-DTC）时，往往疾病进展迅速、病死率高，且目前治疗方法有限。近年来，随着对RAIR-DTC发生发展相关基因突变、信号传导通路、免疫微环境研究的日益深入以及新型核素示踪剂的研发，为其靶向治疗提供了更多的理论依据。

关键词: 碘难治性分化型甲状腺癌, 靶向治疗, 免疫疗法, 肽受体介导的放射性核素治疗